Avsar.

Healthcare · Pharmaceuticals

Marksans Pharma Ltd (MARKSANS)

₹306.20

Mkt cap
₹13,876 Cr
P/E ratio
26.80
P/B
4.59
Div yield
0.29%
ROE
15.20%
ROCE
18.80%
EPS (TTM)
₹11.43
Book value
₹67
52W range
155–351
Sector
Healthcare

Price history

Previous close

Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products [1]

NSE MARKSANSBSE 524404
Health check
Constructive
ValuationCheap
ProfitabilityStrong
GrowthModerate
TechnicalsNeutral
52-week range
−12.75% from high
₹306
₹155+97.55% from low₹351
Current
₹306.20
Prev close
₹315.35
Day
−2.90%
Price performance
1D
−3.01%
1W
+6.61%
1M
−10.77%
3M
+18.27%
6M
+62.89%
1Y
+71.33%
YTD
+68.07%

Financials

Revenue, profit & margin
P/E ratio
26.8×
MARKSANS is 21% below the sector median of 34.0×
MARKSANS26.8×
Sector median34.0×
 Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Trend
Sales500531586560591642682708620720754856841
Expenses398417453450462495543582520576594661628
Operating Profit102114133110128147139127100144161195213
OPM %20%21%23%20%22%23%20%18%16%20%21%23%25%
Other Income101951715-02815622203525
Interest2235333366667
Depreciation14182221202021232327242425
Profit before tax9711411310012012514311677133151200207
Tax %27%26%26%23%26%22%27%22%24%26%25%25%23%
Net Profit708483788998105915899114149159
EPS in Rs1.521.841.841.731.962.132.312.001.292.172.503.273.47
Raw PDF

Earnings

Results dates & reactions
Next results
4 Nov '26scheduled

Fresh quarters land in the Financials table above, tagged NSE until screener catches up.

Avg earnings-day move +12.06% · closed higher next day 1 of last 1
 Q1FY27
Broadcast12 Aug '26
Earnings day+12.06%
+1 day+8.77%
+5 days+17.23%
+15 days+19.20%
+30 days+20.95%
FilingXBRL

Corporate actions

Last 6 months

No recent corporate actions

Dividends, splits, and bonuses in the last six months show up here.

Results analysis

Shareholding

as of Sep 2026
43.87%Promoter
Promoters43.87%
FIIs19.06%1.59
DIIs5.54%0.65
Public31.53%0.93
Ownership trend

Peers

8 companies
Valuation vs quality
P/E × ROCE · bubble = market cap
NameCMPP/EMkt CapDiv YldNP QtrQtr Profit VarSales QtrQtr Sales VarROCE
Sun Pharma.Inds.₹1,777.7034.664,26,5300.90%1,995−10.53%16,199+11.88%20.53%
Divi's Lab.₹9,780.0087.142,59,6280.31%902+65.50%3,080+27.80%21.97%
Torrent Pharma.₹4,613.4080.831,75,4790.82%534−10.03%4,979+50.79%15.19%
Laurus Labs₹2,405.5097.001,29,9720.08%436+126.43%2,206+33.44%17.76%
Zydus Lifesci.₹1,245.5025.521,24,2390.08%990−35.09%8,017+21.96%21.14%
Dr Reddy's Labs₹1,352.0040.301,12,8490.59%913−31.35%8,698−1.48%13.04%
Cipla₹1,378.9035.871,11,3970.94%852−35.05%7,404−2.44%15.49%
Marksans Pharma₹306.2026.8513,8760.29%159+169.50%841+35.62%18.80%
Median: 158 Co.₹426.3834.031,9210.08%14+24.68%175+19.54%15.12%

Filings

Annual reports15
Annual Report 2026Annual Report 2025Annual Report 2024Annual Report 2023Annual Report 2022Annual Report 2021Annual Report 2020Annual Report 2019Annual Report 2018Annual Report 2017Annual Report 2016Annual Report 2015Annual Report 2014Annual Report 2013Annual Report 2013
Concall transcripts58
TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptJun 2026PPTJun 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025RECAug 2025TranscriptMay 2025PPTMay 2025RECMay 2025TranscriptMay 2025TranscriptFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024RECNov 2024TranscriptAug 2024
Credit ratings6
Rating update 7 OctcareRating update 4 JunfitchRating update 6 Oct 2025careRating update 5 Mar 2025fitchRating update 7 Oct 2024careRating update 7 Dec 2023fitch
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 26 Oct - Intimation of schedule for Q2FY27 Earnings Conference CallBoard Meeting Intimation for Declaration Of Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2026 19 Oct - Board meeting on November 4, 2026 to approve Q2 and half-year FY2026 unaudited results.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 13 Oct - Certificate under regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter and half year ended September 30, 2026Closure of Trading Window 25 Sep - Trading window closed from October 1, 2026 until 48 hours after Q2 FY26 results.Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares 17 Sep - SEBI special window opened for re-lodgment of pre-April 2019 physical share transfer requests until February 4, 2027.